May 14th 2024
The artificial intelligence (AI)-powered module provides a prostate segmentation tool for MRI-guided transurethral ultrasound ablation (TULSA) procedures in patients with prostate cancer.
What a Breast MRI Study Reveals About Axillary Lymph Nodes and COVID-19 Booster Vaccination
March 21st 2023In a study of 128 patients who had breast magnetic resonance imaging (MRI) exams after COVID-19 booster vaccination, researchers noted that nearly 19 percent of the cohort had equal to or greater than 0.2 cm of increased lymph node cortical thickness.
Seven Key Considerations with Rectal Cancer MRI
March 3rd 2023In a cum laude awarded presentation at the European Congress of Radiology (ECR), researchers discussed misconceptions and pertinent principles for magnetic resonance imaging (MRI) of patients with rectal cancer, ranging from the diagnosis of mucinous tumors to the impact of mesorectal fascia status for rectal cancer recurrence.
Cancer Screenings and COVID-19: What a New Study Shows
February 27th 2023New research from the American Cancer Society comparing pre-pandemic cancer screening prevalence to the second year of the COVID-19 pandemic in the United States showed a 1.1 million decrease in breast cancer screenings, a 4.4 million decrease in cervical cancer screening and a 600,000 decrease in prostate cancer screenings.
Current Perspectives on the BCLC Staging System for Hepatocellular Carcinoma
February 24th 2023Reviewing recent changes to the Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma and the potential impact for interventional radiologists, these authors discuss key updates including the subdivision of patients with intermediate stage disease and emerging literature on systemic agents for advanced disease.
Can Pre-Op Ultrafast MRI Predict Upgrade of DCIS Lesions to Invasive Breast Cancer?
February 9th 2023In a new study that may have implications for breast cancer surgery, researchers found that shorter time to enhancement (TTE) on preoperative ultrafast magnetic resonance imaging (MRI) was significantly associated with escalation of ductal carcinoma in situ (DCIS) to invasive breast cancer.
Interval Breast Cancer: What a New Mammography Study Reveals
February 6th 2023In a new study of 1,232 women diagnosed with breast cancer within a year of a screening mammography exam, researchers found that interval breast cancer was 17 percent more likely in women with dense or extremely dense breasts, and over three times more likely to involve stage 2 or higher primary tumors in comparison to screening-detected breast cancer.
Can MRI Surveillance Have an Impact in Detecting Recurrence of Soft Tissue Sarcomas?
February 3rd 2023While acknowledging a moderate to high risk of bias in the retrospective studies reviewed for a recent meta-analysis, researchers found the current evidence supports the use of high-intensity magnetic resonance imaging (MRI) surveillance for detection of soft tissue sarcoma recurrence.
New Meta-Analysis Says MRI is Best Supplemental Imaging for Dense Breasts
January 31st 2023In a review of 22 studies and data from over 132,000 women with dense breasts and negative mammography exams, researchers found that magnetic resonance imaging (MRI) was superior to digital breast tomosynthesis, handheld ultrasound and automated whole breast ultrasound for the detection of breast cancer.
Abbreviated MRI and Early-Stage Hepatocellular Carcinoma: What a New Multicenter Study Reveals
January 25th 2023In a multicenter study involving nearly 300 patients, researchers found that abbreviated magnetic resonance imaging (MRI) had a sensitivity rate of 88.2 percent and a specificity rate of 89.1 percent for detecting early-stage hepatocellular carcinoma (HCC).
Meta-Analysis Reaffirms Benefits of O-RADS MRI for Diagnosing Indeterminate Adnexal Lesions
December 16th 2022In addition to summary sensitivity and specificity of 92 percent and 91 percent respectively for characterization of indeterminate adnexal lesions, the meta-analysis on pelvic magnetic resonance imaging (MRI) revealed higher summary malignancy rates for O-RADS MRI 4 and 5 lesions than predicted.
Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?
December 7th 2022The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.
What BI-RADS Changes Are on the Way for Breast MRI Reporting?
December 2nd 2022In a recent lecture at the Radiological Society of North America (RSNA) conference, Wendy DeMartini, MD, discussed a variety of preliminary proposed changes to the Breast Imaging Reporting and Data System (BI-RADS) for breast magnetic resonance imaging (MRI) examinations.
Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?
December 1st 2022In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.
Enhancing MRI Efficiency and Quality: Can the New SIGNA Experience Have an Impact?
November 29th 2022Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.
Current Insights on AI, Breast Cancer Screening and the FDA
November 8th 2022In a recently published article, researchers from Yale University discuss the pros and cons of current FDA regulations as they apply to the clearance and use of adjunctive artificial intelligence (AI) software with conventional breast cancer screening modalities such as mammography.